Registry of Lobbyists

Registration - In-house Corporation

Bayer Inc. / Viktoria Friedrich, Country President and General Manager - Pharmaceutical Division

Registration Information

In-house Corporation name: Bayer Inc.
Responsible Officer Name: Viktoria Friedrich, Country President and General Manager - Pharmaceutical Division 
Responsible Officer Change History
Initial registration start date: 2005-08-19
Registration status: Active
Registration Number: 955828-4969

Associated Communications

Total Number of Communication Reports: 30

Monthly communication reports in the last 6 months: 2

Version 4 of 28 (2007-03-23 to 2007-10-25)

Version 4 of 28 (2007-03-23 to 2007-10-25) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: Bayer Inc.
77 Belfield Road
Toronto, ON  M9W 1G6
Canada
Telephone number: 613-295-8406
Fax number: 416-240-5292  
Responsible officer name and position during the period of this registration: Philip Blake, President and CEO  
Description of activities: Bayer Inc. ("Bayer") is a Canadian subsidiary of Bayer AG, an international research-based group with core businesses in health care, crop science, and innovative materials.Headquartered in Toronto, Ontario, Bayer Inc. operates the Bayer Group's HealthCare and MaterialScience businesses in Canada. Bayer CropScience Inc., headquartered in Calgary, Alberta operates as a separate legal entity in Canada. Together, the companies play a vital role in improving the quality of life for Canadians - producing products that fight diseases, protecting crops and animals, and developing high-performance materials for applications in numerous areas of daily life.
 
The client is a subsidiary of the following parent companies: Bayer AG
51368
Leverkusen
Germany

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: Greg Ball
Position title: Business Head, Institutional
Public offices held: No
 
Name: Norma Beauchamp
Position title: Business Head, Community
Public offices held: No
 
Name: Alan Birrell
Position title: Head, Hematology & Cardiology
Public offices held: No
 
Name: Ute Bockstegers
Position title: CFO and Head of BAP
Public offices held: No
 
Name: Shurjeel Choudhri
Position title: Head, Medical & Scientific Affairs
Public offices held: No
 
Name: Jacqueline DeGagne
Position title: Head - Law and Patents
Public offices held: No
 
Name: Stefan Freeman
Position title: Head - Animal Health Division
Public offices held: No
 
Name: Doug Grant
Position title: VP - Corporate Affairs
Public offices held: No
 
Name: Jim Graziadei
Position title: Head - Diagnostics Division
Public offices held: No
 
Name: Gord Johnston
Position title: Head - Human Resources
Public offices held: No
 
Name: Daniel Lamothe
Position title: Manager, Strategic Partnerships, Hematology Division
Public offices held: No
 
Name: Reine Larose
Position title: Director - Government Affairs and Patient Access, Quebec, Atlantic Canada
Public offices held: No
 
Name: Kory McDonald
Position title: Director, Federal Government Affairs
Public offices held: Yes
 
Name: Paula Moore
Position title: Director, Financial Services
Public offices held: No
 
Name: Russ Newsome
Position title: Head - Diabetes Care Division
Public offices held: No
 
Name: Ernie Springnolo
Position title: Country Representative - Bayer MaterialScience
Public offices held: No
 
Name: Peter Wyles
Position title: Head - Consumer Care Division
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Agriculture and Agri-Food Canada (AAFC), Environment Canada, Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Members of the House of Commons, Natural Resources Canada (NRCan), Patented Medicine Prices Review Board (PMPRB), Privy Council Office (PCO), Senate of Canada
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Agriculture, Consumer Issues, Education, Employment and Training, Energy, Environment, Fisheries, Forestry, Government Procurement, Health, Industry, Intellectual Property, Internal Trade, International Trade, Labour, Science and Technology, Taxation and Finance, Transportation
 
Subject Matter: Retrospective: Proposed Amendments to Schedule A of the Food and Drugs Act and other measures to enhance promotion and regulation of self-care products (Regulation) Proposed Implementation of Health Canada?s ?Blueprint for Renewal? and Progressive Licencing System (Policy or Program) Canada?s environmental policy, including measures to address air quality and climate change (Policy or Program) Consultations on Patented Prices Medicines Review Board (PMBRB) mandate and policies (Policy or Program) Parliamentary Review of the Canadian Environmental Protection Act (CEPA) (Legislative Proposal)Study of the Common Drug Review by the House of Commons Standing Committee on Health (Policy or Program) onsultations on the federal Science and Technology strategy, entitled Mobilizing Science and Technology to Canada?s Advantage (Policy or Program) Measures relating to cross-border trade of health care products. (Policy or Program) Consultations relating to Canada?s economic outlook and Federal Budget (Policy or Program)
Subject Matter: Prospective: Proposed Amendments to Schedule A of the Food and Drugs Act and other measures to enhance promotion and regulation of self-care products (Regulation) Proposed Implementation of Health Canada?s ?Blueprint for Renewal? and Progressive Licencing System (Policy or Program) Canada?s environmental policy, including measures to address air quality and climate change (Policy or Program) Consultations on Patented Prices Medicines Review Board (PMBRB) mandate and policies (Policy or Program) Parliamentary Review of the Canadian Environmental Protection Act (CEPA) (Legislative Proposal)Study of the Common Drug Review by the House of Commons Standing Committee on Health (Policy or Program) Consultations on the federal Science and Technology strategy, entitled Mobilizing Science and Technology to Canada?s Advantage (Policy or Program) Measures relating to cross-border trade of health care products. (Policy or Program)Consultations relating to Canada?s economic outlook and Federal Budget (Policy or Program)
 

Details Regarding the Identified Subject Matter

Categories Description
Legislative Proposal Assisted Human Reproduction Act
Legislative Proposal Canada Labour Code
Legislative Proposal Canadian Environmental Assessment Act
Legislative Proposal Canadian Environmental Protection Act,
Legislative Proposal Competition Act
Legislative Proposal Energy Policy
Legislative Proposal Food and Drugs Act
Legislative Proposal Patent Act
Legislative Proposal Progress towards implementation of the Kyoto Protocol
Legislative Proposal Recyling and Waste Management Initiatives
Legislative Proposal Transportation of Dangerous Goods Regulations,
Legislative Proposal Transportation Policy




Date Modified: